FDA Denies Reata’s New Drug Application for Bardoxolone

By PacConAdmin | February 28, 2022

The FDA has issued a complete response letter (CRL) to Reata Pharmaceuticals, rejecting the company’s new drug application (NDA) for bardoxolone methyl for treatment of patients with Alport syndrome-related chronic kidney disease.
Source: Drug Industry Daily

Posted in Drug Industry Daily